Niacin on Immune Activation : a Proof-of-concept Study
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
There are a number of powerful anti-HIV drugs, which keep the virus at undetectable levels
and enable HIV-infected individuals to live longer. However, some participants taking
anti-HIV drugs do not achieve an adequate CD4 recovery and remain at risk for developing AIDS
and non-AIDS-related complications.
ER niacin (PrNiaspanFCT®) is an extended-released form of niacin, also known as vitamin B3.
Niacin is effective in reducing cholesterol levels in the blood. This drug has been known for
a long-time to treat dyslipidemia and it is used to improve favourably all the lipoprotein
risk factors for artherosclerotic disease, particularly in HIV-infected patients. Recent
scientific research shows that regular consumption of niacin-rich foods may also provide
protection against Alzheimer's disease and age-related cognitive decline.
The purpose of this study is to find out:
1. If ER niacin combined with anti-HIV drugs, compared with anti-HIV drugs alone, could
reduce T cell immune activation and enhance CD4 recovery;
2. If ER niacin can improve your quality of life and your neurocognitive functions
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator:
CIHR Canadian HIV Trials Network
Treatments:
Niacin Niacinamide Nicotinic Acids Vitamin B Complex Vitamins